Literature DB >> 17429071

The RING finger domain of MDM2 is essential for MDM2-mediated TGF-beta resistance.

Christian Kannemeier1, Rong Liao, Peiqing Sun.   

Abstract

In this study, we attempt to gain insights into the molecular mechanism underlying MDM2-mediated TGF-beta resistance. MDM2 renders cells refractory to TGF-beta by overcoming a TGF-beta-induced G1 cell cycle arrest. Because the TGF-beta resistant phenotype is reversible upon removal of MDM2, MDM2 likely confers TGF-beta resistance by directly targeting the cellular machinery involved in the growth inhibition by TGF-beta. Investigation of the structure-function relationship of MDM2 reveals three elements essential for MDM2 to confer TGF-beta resistance in both mink lung epithelial cells and human mammary epithelial cells. One of these elements is the C-terminal half of the p53-binding domain, which at least partially retained p53-binding and inhibitory activity. Second, the ability of MDM2 to mediate TGF-beta resistance is disrupted by mutation of the nuclear localization signal, but is restored upon coexpression of MDMX. Finally, mutations of the zinc coordination residues of the RING finger domain abrogates TGF-beta resistance, but not the ability of MDM2 to inhibit p53 activity or to bind MDMX. These data suggest that RING finger-mediated p53 inhibition and MDMX interaction are not sufficient to cause TGF-beta resistance and imply a crucial role of the E3 ubiquitin ligase activity of this domain in MDM2-mediated TGF-beta resistance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17429071      PMCID: PMC1877115          DOI: 10.1091/mbc.e06-09-0844

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  48 in total

1.  Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53.

Authors:  S Fang; J P Jensen; R L Ludwig; K H Vousden; A M Weissman
Journal:  J Biol Chem       Date:  2000-03-24       Impact factor: 5.157

2.  MdmX protects p53 from Mdm2-mediated degradation.

Authors:  M W Jackson; S J Berberich
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

3.  Different sensitivity of the transforming growth factor-beta cell cycle arrest pathway to c-Myc and MDM-2.

Authors:  S W Blain; J Massagué
Journal:  J Biol Chem       Date:  2000-10-13       Impact factor: 5.157

4.  The contribution of the acidic domain of MDM2 to p53 and MDM2 stability.

Authors:  M Argentini; N Barboule; B Wasylyk
Journal:  Oncogene       Date:  2001-03-15       Impact factor: 9.867

5.  Direct interaction of c-Myc with Smad2 and Smad3 to inhibit TGF-beta-mediated induction of the CDK inhibitor p15(Ink4B).

Authors:  Xin-Hua Feng; Yao-Yun Liang; Min Liang; Weiguo Zhai; Xia Lin
Journal:  Mol Cell       Date:  2002-01       Impact factor: 17.970

6.  Hdmx stabilizes Mdm2 and p53.

Authors:  R Stad; Y F Ramos; N Little; S Grivell; J Attema; A J van Der Eb; A G Jochemsen
Journal:  J Biol Chem       Date:  2000-09-08       Impact factor: 5.157

7.  Growth inhibition by TGF-beta linked to suppression of retinoblastoma protein phosphorylation.

Authors:  M Laiho; J A DeCaprio; J W Ludlow; D M Livingston; J Massagué
Journal:  Cell       Date:  1990-07-13       Impact factor: 41.582

8.  Defining the molecular basis of Arf and Hdm2 interactions.

Authors:  B Bothner; W S Lewis; E L DiGiammarino; J D Weber; S J Bothner; R W Kriwacki
Journal:  J Mol Biol       Date:  2001-11-23       Impact factor: 5.469

9.  The contribution of the RING finger domain of MDM2 to cell cycle progression.

Authors:  M Argentini; N Barboule; B Wasylyk
Journal:  Oncogene       Date:  2000-08-10       Impact factor: 9.867

10.  Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence.

Authors:  Weiping Wang; Joan X Chen; Rong Liao; Qingdong Deng; Jennifer J Zhou; Shuang Huang; Peiqing Sun
Journal:  Mol Cell Biol       Date:  2002-05       Impact factor: 4.272

View more
  3 in total

1.  MDM2 regulates dihydrofolate reductase activity through monoubiquitination.

Authors:  Maria Maguire; Paul C Nield; Timothy Devling; Rosalind E Jenkins; B Kevin Park; Radoslaw Polański; Nikolina Vlatković; Mark T Boyd
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

2.  TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer.

Authors:  Shinako Araki; Jacob A Eitel; Christopher N Batuello; Khadijeh Bijangi-Vishehsaraei; Xian-Jin Xie; David Danielpour; Karen E Pollok; David A Boothman; Lindsey D Mayo
Journal:  J Clin Invest       Date:  2009-12-01       Impact factor: 14.808

3.  Opposite regulation of MDM2 and MDMX expression in acquisition of mesenchymal phenotype in benign and cancer cells.

Authors:  Eva Slabáková; Gvantsa Kharaishvili; Monika Smějová; Zuzana Pernicová; Tereza Suchánková; Ján Remšík; Stanislav Lerch; Nicol Straková; Jan Bouchal; Milan Král; Zoran Culig; Alois Kozubík; Karel Souček
Journal:  Oncotarget       Date:  2015-11-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.